CellARTs

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, CellARTs sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

CellARTs: 1 sponsored US clinical trial, 1 recruiting.

CellARTs sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sterility, Male, with 1 trials.

Mid-pack sponsor footprint

CellARTs is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 1

Spermatogonial Differentiation Via Testicular Organoid

NCT06841861

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

Sterility, Male 1
Gene Abnormality 1
Infertility, Male 1

What is open in the CellARTs pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Sterility, Male (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

CellARTs: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

CellARTs sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share CellARTs1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
CellARTs sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

CellARTs sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this CellARTs page

1 registered trials is a research-attention snapshot, not an endorsement of CellARTs or any single study.

  • 1 of CellARTs's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Sterility, Male is the condition CellARTs studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sterility, Male trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

CellARTs pipeline card: 1 registered trials from official public datasets.Report a data error.